Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...

DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe ...

In a new study in the journal Diabetes Technology & Therapeutics (DTT), investigators evaluated the accuracy of the 15.5-day ...

AI-enhanced glucose monitoring provides predictive analytics and personalized insights for better blood sugar management.

Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...

DexCom, Inc. (NASDAQ ... the Middle East and North Africa—90-95%6,7 of whom have Type 2 diabetes. “With policymakers increasingly focused on digital transformation in healthcare, now is ...

Adults with insulin-treated type 2 diabetes had greater HbA1c reductions and larger improvement in time in range with use of ...

Over 13 weeks, drops in HbA1c averaged 0.9 percentage points (from 8.2% at baseline to ... Diabetes Care's t:slim X2 insulin pump with Control-IQ+ technology, used in conjunction with a Dexcom ...

DexCom's growth is slowing ... The valuation of DXCM at 43x non-GAAP forward P/E and 7.5x forward price to sales does not adequately factor in these emerging risks. Given the current competitive ...